Member Special - Advances in Hormone Science Research-Genomic Approaches to Understanding Hormone-Dependent Cancer and Resistance

Video Transcription

Video Summary

Summary 1: The video features Wilbert Zwart discussing the role of androgen receptor enhancers in prostate cancer development. He presents two unpublished stories, one on epigenetic biomarkers in response to therapy in metastatic castration-resistant prostate cancer (MCRPC) and the other on neoadjuvant therapy. In the MCRPC study, they identified biomarkers that predicted therapy resistance, while in the neoadjuvant study, they found that certain genomic sites became active after treatment and were associated with poorer therapy response. Wilbert's research provides insights into genomic aspects of hormone-dependent cancer and resistance, offering potential biomarkers for predicting therapy response and outcomes in prostate cancer.<br /><br />Summary 2: Dr. Wheathill-Grey discusses the importance of understanding intra-tumor heterogeneity in cancer prognosis. She presents her research findings, which show that variation in gene expression and genetic mutations within individual tumors, known as intra-tumor heterogeneity, can have important implications for cancer prognosis. For some cancer types, higher tumor cell transcriptome ploidy is associated with worse prognosis, while for others, lower ploidy is associated with worse prognosis. Dr. Grey highlights the need for personalized approaches to cancer treatment based on the complex nature of tumor heterogeneity.

Keywords

Wilbert Zwart

androgen receptor enhancers

prostate cancer development

epigenetic biomarkers

MCRPC

neoadjuvant therapy

therapy resistance

genomic sites

hormone-dependent cancer

predicting therapy response

intra-tumor heterogeneity

cancer prognosis


EndoCareers \| Contact Us \| Privacy Policy \| Terms of Use	CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.	2055 L Street NW, Suite 600 \| Washington, DC 20036 202.971.3636 \| 888.363.6274